

Menka Khoobchandani
Subhajit Ghosh *Editors*

Medicinal Applications of Phytopharmaceuticals

 Springer

Medicinal Applications of Phytopharmaceuticals

Menka Khoobchandani • Subhajit Ghosh
Editors

Medicinal Applications of Phytopharmaceuticals

 Springer

Chapter 4

Phytochemicals for Preventing and Treating Chronic Diseases



Gerardo N. Guerrero-Flores, Belén Carlino, Rocío V. Gili, Sara Leeson, and Martin L. Mayta

Abstract The rise of noncommunicable diseases (NCDs) as the leading threat to global health is clear, as these conditions cause nearly two-thirds of deaths worldwide, mostly in low and middle-income countries. NCDs are chronic conditions that last 1 year or more and that require medical care and lifestyle changes. Diet is one factor contributing to NCDs. While diets high in fruits, vegetables, nuts, and whole grains protect against developing several NCDs, increased mortality has been associated with a high intake of fried food, red meat, and processed meats. Phytochemicals, plant-derived bioactive compounds, have gained attention for their potential to benefit health and prevent or treat NCDs. Interestingly, phytochemicals interact with the gut microbiota that colonizes the human digestive system, which plays a crucial role in maintaining health and preventing diseases like metabolic syndrome and associated risk factors like insulin resistance and hypertension. This chapter aims to provide a comprehensive understanding of the role of phytochemicals in some chronic diseases and their prevention.

Keywords Noncommunicable diseases · Phytochemicals · Microbiota · Inflammation · Plant-based diet · Lifestyle

G. N. Guerrero-Flores (✉)

Centro Interdisciplinario de Investigaciones en Ciencias de la Salud y del Comportamiento (CIICSAC), Universidad Adventista del Plata, Libertador San Martín, Entre Ríos, Argentina

Faculty of Medical Sciences, National University of Rosario (UNR), Rosario, Argentina

e-mail: gerardo.guerrero@uap.edu.ar

B. Carlino · R. V. Gili · S. Leeson

Centro Interdisciplinario de Investigaciones en Ciencias de la Salud y del Comportamiento (CIICSAC), Universidad Adventista del Plata, Libertador San Martín, Entre Ríos, Argentina

M. L. Mayta

Centro Interdisciplinario de Investigaciones en Ciencias de la Salud y del Comportamiento (CIICSAC), Universidad Adventista del Plata, Libertador San Martín, Entre Ríos, Argentina

Molecular Biology Department, School of Pharmacy and Biochemistry, Universidad Nacional de Rosario (UNR), Rosario, Argentina

4.1 Introduction

Noncommunicable diseases (NCDs) have been defined as conditions that last 1 year or beyond, requiring constant medical care and changes in lifestyle activities, or both [1, 2]. With NCDs accounting for nearly two-thirds of deaths worldwide, mainly from low/middle-income countries [3], the emergence of chronic diseases as the predominant challenge to global health is undeniable [4]. One of the factors contributing to the development of chronic conditions is diet [5]. Previous studies have identified the relationship between diet and mortality. A plant-based diet exerts a protective effect against the development of several chronic diseases, such as hypertension [6, 7], metabolic syndrome [8], diabetes mellitus [9, 10], and ischemic heart disease (IHD) [11, 12], which might be expected to result in lower mortality [13]. Those foods found to correlate with reduced mortality include nuts [14, 15], fruit, vegetables [16], cereal fiber [17], polyunsaturated fatty acids (PUFAs) [18], and green salad [19]; while association with increase mortality have been found for meat, red meat, processed meat [20], eggs [21], and fried potatoes [22].

Phytochemicals are plant-derived bioactive compounds classified as primary and secondary metabolites, according to their function in plant metabolism [23]. Primary metabolites, such as carbohydrates, lipids, and proteins, are directly involved in plant growth and metabolisms [24], while secondary metabolites are further grouped into three main classes: alkaloids, glucosinolates, and cyanogenic glycosides; phenolic compounds; and terpenes. These secondary metabolites in plants serve a variety of ecological and physiological functions. Phytochemicals have gained considerable attention for their potential to positively impact health and prevent or treat noncommunicable diseases like obesity, type 2 diabetes, cancer, and cardiovascular disease [25, 26]. A growing body of evidence shows a significant correlation between phytochemicals intake levels and their positive effects on NCDs [27, 28] (Table 4.1). Phytochemicals are important bioactive compounds that can prevent cardiovascular diseases (CVDs) through several mechanisms. For example, many studies have thoroughly examined how flavonoids can interfere with lipid metabolism, decrease platelet adhesion, and improve endothelial function [93–96]. Moreover, studies have shown that phytochemicals possess antidiabetic qualities, as they improve pancreatic function, glucose homeostasis, and insulin sensitivity [97]. Recent research has also uncovered phytochemicals' anticancer properties, with compounds like sulforaphane in cruciferous vegetables and curcumin in turmeric demonstrating potent antiinflammatory and antioxidant effects that can modulate signaling pathways involved in cancer development [25, 98–100].

Additionally, an intriguing relationship exists between phytochemicals and the gut microbiota (the bacteria, archaea, and eukaryotes that colonize the human digestive system). The gut microbiota impacts human health from innate immunity to appetite and energy metabolism [101, 102]. For example, phytochemicals influence microbiota composition in a way that hinders colorectal cancer development [103], and phytochemicals interaction with the microbiota may help prevent metabolic syndromes and its associated risk factors, like insulin resistance and hypertension, which heighten cardiovascular disease and diabetes risk [104]. The complex

Table 4.1 Dietary phytochemicals for prevention and treatment of NCDs

Chronic disease	Natural compound	Activity	Refs.
<i>Diabetes</i>	Anthocyanin	Improved glucose metabolism and insulin sensitivity	[29]
	Stigmasterol	Improved hyperglycemia	[30]
	Genistein diglucuronide	Lower T2DM risk	[31, 32]
	Dihydrocaffeic acid	Lower T2DM risk; lower concentrations of plasma glucose	
	P-Coumaric, ferulic, caffeic acids and quercetin	α -Amylase and α -glucosidase inhibitory activities	[33]
	Resveratrol	Substantial decrease in homeostatic model assessment of insulin resistance (HOMA-IR) and insulin levels	[34]
		It improves glucose and insulin metabolism	[35]
	Catechin, gallic, protocatechuic acids, and quercetin	α -Amylase and α -glucosidase inhibitory activities	[36]
			[37]
	Gallic, p-coumaric acid, and Tyrosol		
	Isoflavones and lignans	Improved glucose uptake in animal studies, but inconsistent results in humans	[38]
	Quercetin	Exerted effects on insulin release via changes in Ca^{2+} metabolism	[39]
		Reduced intestinal absorption of glucose, improves glucose absorption in tissues and organs; and improves insulin resistance	[40]
		Improved the function of pancreatic β cells through adenosine monophosphate-activated protein kinase (AMPK), among other mechanisms	[41]
Vitexin, isovitexin and isorhamnetin rutinoides	α -Glucosidase inhibitory effects	[42]	
γ -Sitosterol	Increased insulin secretion in response to glucose	[43]	
Naringenin	Reduced glucose adsorption by the intestinal brush border, reduced renal glucose reabsorption, and increased glucose uptake and utilization	[43, 44]	
Rutin	Improves glycemic status	[45]	
Curcumin	Improved β -cell functions, prevents β -cell death, and decreases insulin resistance	[46]	

(continued)

Table 4.1 (continued)

Chronic disease	Natural compound	Activity	Refs.
<i>Cardio-vascular disease</i>	Ellagitannin	Inhibited proliferation of myocardial fibrosis	[47]
	Curcumin	Decreased oxidative stress and fibrosis	[48]
		Promoted mitochondria function; Prevents apoptosis	[49]
	Icariin	Inhibits of myocardial apoptosis and prevention of inflammation on endothelial cell injury	[50]
	Ferulic acid	Vasorelaxation	[51]
	Resveratrol	Activated SIRT-1 (a class III histone deacetylase), eNOS, Nrf2, and antioxidant response element (ARE), and decreases TNF α production	[52]
	(+)-Catechin	Reduced NF- κ B activation; reduction of ICAM-1 and E-selectin adhesion molecules	[53]
	(-)-Epicatechin		
	Procyanidin dimer B2		
	Quercetin	Antihypertensive, hypolipidemic, hypoglycemic, anti-atherosclerotic, and cardioprotective	[54]
	Procyanidin trimer C1	Promoted Ca ²⁺ -mediated signals such as the hyperpolarization via multiple K ⁺ channel activations and the Nitric Oxide release in rat aortic endothelial cells	[55]
	Cinnamtannin A2	Protected low-density lipoprotein from oxidation	[56]
	<i>Cancer</i>	Glucosinolate	Promotes apoptosis and inhibits proliferation of human liver cancer cells
Induced senescence and apoptosis of human breast cancer cells; stimulated tumor suppressors; Inhibited tumor growth			[58]
Stimulated tumor suppressors			[59]
Reduced melanoma cell viability			[60]
Enhanced gap junction activity and chemotherapy sensitivity; improved dendritic cell activity; activated tumor suppressor gene			[61]
Inhibits tumor progression			[62]
Baicalin		Inhibits proliferation of cancer cells	[63]
		Inhibited tumor growth and progression	[64]
Daidzein		Inhibited tumor growth	[65]
		Promoted tumor growth	
Epigallocatechin-3-gallate		Eliminated toxic compounds and inhibits growth of cancer cells	[66]
Emodina		Suppressed the growth of various tumor cell lines	[67]
Ellagic Acid		Anti-proliferative and apoptotic effects	[68]
6-Shogaol		Akt and STAT signaling	[37]
Allicin		Suppressed cell proliferation and invasion via STAT3 signaling and may be a potential therapeutic agent	[69]
Alpinumisoflavone		Suppressed tumor growth and metastasis of clear-cell renal cell carcinoma	[70, 71]
Andrographolide		Suppressed cell proliferation and inducing cell apoptosis via inactivation of ER- α receptor and PI3K/AKT/mTOR signaling	[72]
Apigenin	Cell growth arrest and apoptosis	[73]	
Curcumin	Modulated cell signaling and gene expression regulatory pathways	[74]	

(continued)

Table 4.1 (continued)

Chronic disease	Natural compound	Activity	Refs.
	Dicumarol	Inhibited PDK1 and targets multiple malignant behaviors of ovarian cancer cells	[75]
	Genistein	Inhibited AKT phosphorylation and suppression of GSK-3 β dephosphorylation. Promotes β -catenin phosphorylation	[76]
	Gingerol	Induced apoptosis in the bladder cancer cell	[77]
	Glycyrrhizin	JAK/STAT signaling pathway	[78]
	Hispidulin	Intrinsic apoptosis pathway	[79]
	Licochalcone A	Induced cell cycle arrest in human lung squamous carcinoma cells <i>via</i> the PI3K/Akt signaling pathway	[80]
	Nimbolide	PI3K/AKT/mTOR and ERK signaling	[81]
	Physapubescin B	Ki-67, Cdc25C, and PARP	[82]
	Pterostilbene	Anti-tumor activity in ovarian cancer via anti-proliferative and pro-apoptotic mechanisms, possibly via downregulation of JAK/STAT3 pathway	[83]
	Resveratrol	Regulated cell cycle and apoptosis pathways	[84]
	Sulforaphane	Cell cycle arrest and apoptosis. Targets: caspase 8, p21, hsp90	[85]
	Thymol	Mitochondrial mediated apoptosis	[86]
	Thymoquinone	Induced the apoptosis of A431 cells through generation of ROS and inhibition of STAT3 signaling	[87]
	Ursolic acid	Inhibited the growth of human pancreatic tumors and sensitized them to gemcitabine by suppressing inflammatory biomarkers linked to proliferation, invasion, angiogenesis, and metastasis	[88]
	Withaferin-A	Modulated the expression and activity of different oncogenic proteins	[89]
	Ellagitannin	Reinforced gut barrier function	[90]
<i>Inflammatory disease</i>	Curcumin	Reduced inflammation and oxidative stress	[91]
	Baicalin	Inhibited pyroptosis and inflammation	[92]

interplay between phytochemicals and health highlights the promising potential of plant-based treatments to reduce the global burden of NCDs. This chapter aims to provide a comprehensive understanding of the role of phytochemicals in some chronic diseases and their prevention.

4.2 Phytochemicals, Microbiota-derived Metabolites, and Their Influence on NCDs

The human gut microbiome is a fascinating microbial universe living in the digestive system [105, 106]. In newborns, a complex community of bacteria, archaea, and eukaryotes develops based on the method of birth, whether the newborn is breastfed, and the exposure to environmental microbes. The microbiota plays a critical role in human health (Fig. 4.1) [107, 102], influencing everything from immune function to metabolism [108–110]. Most of the body's microbiota resides




Fig. 4.1 Schematic representation of the crosstalk between the human microbiome and noncommunicable diseases. Microbiota plays a critical role in the development and progression of obesity, diabetes, immune function, heart disease, cancer, and neurological disorders

in the colon [111] and constantly influences the host's health by digestion and absorption of nutrients [112, 113]; production of energy [113], hormones [114], neurotransmitters [115], and vitamins [116]; modulation of the immune system [117]; and protection against pathogens and exogenous toxins [118]. Multiple factors play a crucial role in shaping the gut microbiota [119], and later in life, medications, diseases, genetics, and lifestyle preferences can alter the microbiota composition [120–123], being the diet the most influential factor in the gut microbiota and human health [124]. Phytochemicals can selectively enhance the growth of microbes [125], and the fermentation of non-digestible polyphenols by gut microbes generates beneficial polyphenolic compounds providing significant protection against many chronic diseases [111, 126–130]. Phytochemical beneficial effects likely involve microbiota, either by altering microbial metabolites or by interacting with host cells. For instance, ellagic acid, a polyphenol found naturally in many plants, is metabolized by colonic bacteria into urolithins, a class of anticancer agents (Fig. 4.2) [47, 111, 130–136].




Fig. 4.2 Ellagic acid-containing foods are converted by gut microbes into various forms of urolithins. Urolithin A exhibits biological activities like reducing inflammation and enhancing mitophagy. Urolithin B demonstrates additional benefits, including cardiovascular and nephroprotection, neuroprotection, anti-carcinogenic, antidiabetic, anti-inflammatory, antioxidant, and antibacterial properties

4.2.1 *Phytochemicals and Heart Diseases*

Cardiovascular diseases (CVDs) remain the leading cause of death and disability in the USA and globally [137]. The principal risk factors for CVD involved are high blood cholesterol, higher body mass index (BMI), high blood pressure, glucometabolic disorders, and diabetes [138, 139]. Studies indicated that compared to omnivorous diets, vegetarian diets based on plant food groups such as fruits, whole grains, legumes, vegetables, nuts, and seeds are associated with considerable reductions in several modifiable risk factors; in contrast, incorporating animal products in the diet is positively associated with the risk to develop CVDs [11, 140–142].

Cohort studies, systematic reviews, and meta-analyses have shown that vegan and vegetarian diets improve various cardiometabolic risk markers, including blood lipids and body weight [11, 21, 138, 141, 143, 144], and compared with non-vegetarians, vegetarians have a lower risk of CVD and IHD mortality, respectively [144]. Moreover, blood pressure levels in those with a plant-based diet were also lower than meat eaters, and a reduced prevalence of metabolic syndrome and type 2 diabetes mellitus (T2DM)—prime risk conditions for CVD and stroke—was observed in vegan and vegetarian participants of the Adventist Health Study-2 (AHS-2) [8, 9]. These differences in the AHS-2 occurred although the non-vegetarians in this cohort eat less meat than the general population [11, 12]. Interestingly, clinical intervention studies utilizing plant-based eating patterns have additionally demonstrated the reversal of coronary artery disease in cardiovascular disease patients [11, 12, 145].

Plants contain many protective nutrients and phytochemicals such as flavonoids, polyphenols, sterols, sulfur compounds, and terpenoids [146–148]. Studies indicate that these compounds provide cardiovascular benefits: flavonoids prevent low-density lipoprotein oxidation and improve vasodilation; plant sterols reduce cholesterol absorption; sulfur compounds activate antioxidant pathways; quinones boost mitochondrial ATP production; and terpenoids decrease atherosclerotic lesions on the aortic valve [149–153]. By providing these cardioprotective effects, the phytochemicals abundant in plants may explain the more favorable cardiometabolic risk profile observed in vegetarians compared to non-vegetarians.

Gut Microbiota, Phytochemicals, and Cardiovascular Diseases In recent years, studies evaluated how gut microbiota can directly modulate coronary artery diseases [154]. Research has shown that certain polyphenol-rich compounds can beneficially modulate the gut microbiota and reduce risk factors for cardiovascular disease. For example, correlation analysis has revealed a significant association between gut microorganisms such as *Roseburia*, bioactive phenolic metabolites -from *Aronia melanocarpa*- in plasma, and improved vascular function [155, 156]. Resveratrol increases *Prevotella*, *Akkermansia*, *Lactobacillus*, and *Bifidobacterium* bacteria, which correlates with reduced microbial production of trimethylamine-N-oxide (TMAO), an atherosclerosis risk factor [157]. Hesperidin increases *Lactobacillus* bacteria in the body and improves cardiovascular health by improving endothelial function, which enhances blood flow [158]. Furthermore, peanut skin extract, rich

in procyanidins, catechin, and epicatechin, increases *Roseburia*, *Akkermansia*, and *Bifidobacterium* abundance and reduces atherosclerotic plaques [159]. Moreover, the administration of curcumin promoted weight loss in mice with obesity and hepatic steatosis induced by a high-fat diet, an effect associated with the growth of short-chain fatty acid-producing bacterial species, including *Bacteroides*, *Akkermansia*, *Parabacteroides*, *Alistipes*, and *Alloprevotella* [160]. Additionally, the proanthocyanidin found in wild blueberries reduces obesity by promoting the growth of the gut bacteria *Akkermansia muciniphila* and goblet cells [161]. On the other hand, studies that autotransplant fecal microbiota combined with a Mediterranean diet rich in polyphenols have been shown to increase the proliferation of beneficial bacteria, such as *Bacteroides massiliensis* and *Paraprevotella clara*, which attenuate weight gain, and maintain glycemic control [162].

4.2.2 Cancer and Phytochemicals

Cancer is one of the leading causes of death worldwide [163–165]. Estimates suggest that around 40% of cancer cases could be preventable by modifying risk factors [166] such as reducing tobacco use, increasing physical activity, controlling weight, restraining alcohol, and improving diet [167, 168]. Diet-related factors alone are thought to account for about 30% of cancers in developed countries [169]. Evidence from two large cohort studies of vegetarian populations—AHS-2 and the European Prospective Investigation into Cancer and Nutrition-Oxford (EPIC-Oxford)—suggests that increased consumption of nuts, fruits, legumes, and vegetables is associated with decreased overall cancer risk and cancer mortality [13, 170, 171]. Consumption of red meat has been associated with higher mortality from cancer overall, non-Hodgkin lymphoma, and cancers of the bladder, breast, colon, endometrium, esophagus, stomach, lung, and nasopharynx. Additionally, eating processed meats may increase the risk of death from cancer in general, non-Hodgkin lymphoma, and cancers of the bladder, breast, colon, esophagus, stomach, nasopharynx, oral cavity, oropharynx, and prostate [171–173].

Phytochemicals from fruits, vegetables, and other plant sources have promising anticancer effects [174, 175]. Some phytochemicals act as chemopreventive agents that inhibit tumor formation [176], while others have potential cancer treatments [177, 178]. These phytochemicals target molecular pathways involved in cancer growth and progression through mechanisms like carcinogen deactivation, antioxidant effects, halting proliferation, inducing apoptosis, and immune system modulation [177]. Ellagic acid, for example, a polyphenol present in walnuts, berries, pomegranates, and grapes [179], demonstrates antiproliferative effects against certain cancers [68, 132]. Resveratrol, found in grapes, berries, and peanuts, exhibits activity against breast, cervical, uterine, blood, kidney, liver, eye, bladder, thyroid, esophageal, prostate, brain, lung, skin, gastric, colon, head and neck, bone, ovarian, and cervical cancers [180]. Allicin, a compound derived from garlic, also shows promising benefits [181].

Gut Microbiota, Phytochemicals, and Cancer A healthy gut microbiome can protect against cancers, though the mechanism remains unclear. For example, curcumin has demonstrated anticancer properties that are facilitated by the gut microbiome [182]. A 6-month observational study revealed that a combination of curcumin and quercetin reduced the number and size of polyps by over 50% in patients with an inherited form of colorectal cancer [183], however, bacteria were not a factor evaluated in this particular study. Additionally, green tea polyphenols substantially delayed the development of estrogen receptor-negative mammary tumors and increased populations of *Adlercreutzia* and *Lactobacillus* in a transgenic mice model [184]. Furthermore, administering a polyphenol from *Myrciaria dubia* (Camu camu) increased *Ruminococcaceae* growth and CD8+ T cells in the tumor microenvironment [185], consequently regulating the effectiveness of therapy against cancers [186].

4.2.3 *Phytochemicals and Type 2 Diabetes Mellitus*

The global prevalence of diabetes mellitus, especially T2DM, is rising sharply, as reported in the 2019 and 2021 editions of the Diabetes Atlas [187]. According to statistics, diabetes affected an estimated 537 million people between the ages of 20 and 79 years worldwide in 2021. Experts project this number will rise to 783 million cases globally by the year 2045 [188]. Type 2 diabetes mellitus can lead to numerous health complications like kidney disease, nerve damage, and vision loss, making it a leading cause of various chronic metabolic conditions [189]. The current treatment for T2DM relies on drugs that improve insulin sensitivity, supplement insulin levels, stimulate insulin secretion, or enhance glucose absorption [190]. For example, Metformin is one of the most used drugs for treating T2DM, but it can cause side effects ranging from mild to severe, which may lead patients to stop taking their medication as prescribed [191]. However, alongside pharmacological interventions, dietary plans focusing on balanced nutrition and portion control usually are also part of the treatment.

Combined therapies with medications that have different mechanisms of action can provide greater therapeutic control. These often include a glucagon-like peptide 1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor [192]; nevertheless, therapies using multiple drugs may appear effective, but they can cause problems like toxicity, and side effects due to the complex pharmacological interactions [193]. Conversely, research indicates that people with T2DM benefit from phytochemicals due to their effectiveness, affordability, and probable low side effects [194, 195]. Studies have identified around 1200 plants rich in bioactive compounds with antidiabetic properties, with 400 specifically targeting T2DM [196–198]. Consequently, managing T2DM with phytochemicals appears to be a highly promising and appealing approach.

The Mediterranean and a plant-based diet consisting of whole grains, legumes, vegetables, and fruits contain compounds such as phenolics, carotenoids, and

vitamins that may improve glycemic control and protect against T2DM and its complications [199–202]. Animal research shows that plant extracts containing high levels of phytochemicals exhibit antidiabetic effects equal to or better than some standard antidiabetic medications [203–206]. Several phytochemicals from plant food also have antihyperglycemic properties and disease-modifying effects [178, 195, 196, 203, 204]. Other phytochemicals including flavonoids, saponins, pectin, glucosides, and myrcelin have also demonstrated antidiabetic potential in studies [194].

The mechanisms by which phytochemicals produce their antidiabetic effect include (a) increasing insulin secretion, (b) improving insulin sensitivity, and (c) mimicking insulin action [207, 208]. For example, an 8-week study in humans found an extract of flavonoids, flavonol aglycones, phenolic acids, and steroid glycosides from the *Balanites aegyptiaca* fruit (desert date) significantly reduced postprandial plasma glucose, suggesting it improved insulin sensitivity by lowering fat levels [209]. Additionally, the consumption of 2 g of chocolate with 70% cocoa content was associated with improved fasting plasma glucose and insulin resistance parameters compared to milk chocolate, likely because it contains more flavonoids [210]. Resveratrol and quercetin, two phytochemicals extensively studied for their potential to prevent and treat diabetes, have demonstrated promising results. Resveratrol improves glucose metabolism and lipid profiles in patients with T2DM taking oral medication or insulin, according to multiple studies [34, 35, 211, 212]. Quercetin enhances glucose metabolism and pancreatic beta-cell function to lower plasma glucose levels [40, 213, 214].

The fight against diabetes is intensifying, indicating a need to break with some traditional medicine paradigms and combine conventional treatments with plant-based products. In coming years, prevention and treatment of this disease may shift toward a more holistic approach, as no plant compound nutraceutical or food derivative currently substitutes directly for antidiabetic drugs. A strategy prioritizing a diet high in plant-based foods will yield better outcomes than conventional medications alone.

Gut Microbiota, Phytochemicals, and T2DM Altered glucose homeostasis correlate with changes in gut microbiota composition and the progression of T2DM and its complications [215]. Both animal models and human studies show certain microbiota impact glucose metabolism in T2DM [216]. For example, higher ratios of *Bacteroidetes* to *Firmicutes* and *Bacteroides-Prevotella* to *Clostridium coccoides-Eubacterium rectale* positively correlate with plasma glucose, linking intestinal microbiota to T2DM [217]. Additionally, T2DM patients tend to have lower levels of beneficial *Bacteroides*, *Prevotella*, and *Bifidobacterium* genera. *Bifidobacterium* provides health benefits including improved gut permeability, reduced endotoxin, and inflammation, along with enhanced glucose tolerance, insulin secretion, and attenuated inflammation. Genera like *Bifidobacterium*, *Bacteroides*, *Faecalibacterium*, *Akkermansia*, and *Roseburia* associate negatively with T2DM, while *Ruminococcus*, *Fusobacterium*, and *Blautia* correlate positively.

Furthermore, obesity and T2DM are linked to depleted butyrate-producing bacteria in the *Clostridiales* order [218, 219]. Butyrate is a key compound that supports proper pancreatic beta cell function, especially post-meal. Overall, adequate

butyrate is associated with improved insulin response, while abnormal propionate is associated with T2DM risk, both inducing inflammation [215, 220]. The characterization of gut microbiota dysbiosis in various diseases and the establishment of a causal relationship between gut microbiota and disease can be valuable in developing therapeutic interventions for T2DM and its associated complications [221].

4.2.4 Gut Microbiota and Neurological Diseases

A healthy gut with diverse microbes is vital for normal brain functions and emotional behaviors [222]. There is a well-established relationship between gut microbiota and various neurological diseases, including anxiety, Alzheimer's disease, and depression [223–228]. The diversity of gut microbes is vital for normal brain functions and emotional behaviors. For example, curcumin reversed anxiety-related behaviors in an anxious mouse model by upregulating *Muribaculaceae*, which counteracted the harmful effects of dextran sulfate sodium salt [227]. In another murine Alzheimer's model, quercetin significantly reduced attention deficit symptoms and parameters; this improvement correlated with an increased abundance of *Barnesiella*, *Lactobacillus*, and *Parasutterella* genera [226]. Additionally, higher blood carotenoid levels in humans were associated with a lower risk of developing depressive symptoms [228].

Studies of the gut–brain axis in the future will need to address research questions regarding the gut microbiota and associated neurological disorders in order to provide valuable insights into the beneficial or pathological role of the gut microbiota on the brain.

4.3 Conclusion

Chronic noncommunicable diseases are a major global health threat, causing most deaths in low and middle-income countries. High intake of animal-derived food has been linked to increased mortality, while diets rich in fruits, vegetables, nuts, and whole grains protect against NCDs. Phytochemicals, bioactive compounds from plants, and their interaction with the microbiota have potential health benefits. Combining conventional treatments with plant-based products may be necessary to fight NCDs.

Conflicts of Interest The authors declare no conflict of interest.

References

1. Airhihenbuwa CO, Tseng T-S, Sutton VD, Price L (2021) Global perspectives on improving chronic disease prevention and management in diverse settings. *Chronic Dis* 18:210055. <https://doi.org/10.5888/pcd18.210055>
2. Olivares DEV, Chambi FRV, Chañi EMM et al (2017) Risk factors for chronic diseases and multimorbidity in a primary care context of Central Argentina: a web-based interactive and cross-sectional study. *Int J Environ Res Public Health* 14:251. <https://doi.org/10.3390/ijerph14030251>
3. Tian M, Chen Y, Zhao R et al (2011) Chronic disease knowledge and its determinants among chronically ill adults in rural areas of Shanxi Province in China: a cross-sectional study. *BMC Public Health* 11:1–9. <https://doi.org/10.1186/1471-2458-11-948>
4. Bauer UE, Briss PA, Goodman RA, Bowman BA (2014) Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. *Lancet* 384:45–52. [https://doi.org/10.1016/S0140-6736\(14\)60648-6](https://doi.org/10.1016/S0140-6736(14)60648-6)
5. Gropper SS (2023) The role of nutrition in chronic disease. *Nutrients* 15:1–3. <https://doi.org/10.3390/NU15030664>
6. Feng HP, Yu PC, Huang SH et al (2023) The benefit of vegetarian diets for reducing blood pressure in Taiwan: a historically prospective cohort study. *J Health Popul Nutr* 42:1–10. <https://doi.org/10.1186/S41043-023-00377-3/TABLES/6>
7. Pettersen BJ, Anousheh R, Fan J et al (2012) Vegetarian diets and blood pressure among white subjects: results from the Adventist Health Study-2 (AHS-2). *Public Health Nutr* 15:1909–1916. <https://doi.org/10.1017/S1368980011003454>
8. Rizzo NS, Sabaté J, Jaceldo-siegl K, Fraser GE (2011) Vegetarian dietary patterns are associated with a lower risk of metabolic syndrome the Adventist Health Study 2. *Diabetes Care* 34:1225–1227. <https://doi.org/10.2337/dc10-1221>
9. Tonstad S, Stewart K, Oda K et al (2013) Vegetarian diets and incidence of diabetes in the Adventist Health Study-2. *Nutr Metab Cardiovasc Dis* 23:292–299. <https://doi.org/10.1016/J.NUMECD.2011.07.004>
10. Papier K, Appleby PN, Fensom GK et al (2019) Vegetarian diets and risk of hospitalisation or death with diabetes in British adults: results from the EPIC-Oxford study. *Nutr Diab* 9(1):1–8. <https://doi.org/10.1038/s41387-019-0074-0>
11. Matsumoto S, Beeson WL, Shavlik DJ et al (2019) Association between vegetarian diets and cardiovascular risk factors in non-Hispanic white participants of the Adventist Health Study-2. *J Nutr Sci* 8:e6. <https://doi.org/10.1017/JNS.2019.1>
12. Tong TYN, Appleby PN, Bradbury KE et al (2019) Risks of ischaemic heart disease and stroke in meat eaters, fish eaters, and vegetarians over 18 years of follow-up: results from the prospective EPIC-Oxford study. *BMJ* 366:L4897. <https://doi.org/10.1136/BMJ.L4897>
13. Orlich MJ, Singh PN, Sabaté J et al (2013) Vegetarian dietary patterns and mortality in Adventist Health Study 2. *JAMA Intern Med* 173:1230–1238. <https://doi.org/10.1001/JAMAINTERNMED.2013.6473>
14. Jaceldo-Siegl K, Haddad E, Oda K et al (2014) Tree nuts are inversely associated with metabolic syndrome and obesity: The Adventist Health Study-2. *PLoS One* 9:85133. <https://doi.org/10.1371/journal.pone.0085133>
15. Fraser GE, Sabate J, Beeson WL, Strahan TM (1992) A Possible protective effect of nut consumption on risk of coronary heart-disease: the adventist health study. *Arch Intern Med* 152:1416–1424. <https://doi.org/10.1001/ARCHINTE.1992.00400190054010>
16. Bertoaia ML, Mukamal KJ, Cahill LE et al (2015) Changes in intake of fruits and vegetables and weight change in United States men and women followed for up to 24 years: analysis from three prospective cohort studies. *PLoS Med* 12:e1001878. <https://doi.org/10.1371/JOURNAL.PMED.1001878>

17. Huang T, Xu M, Lee A et al (2015) Consumption of whole grains and cereal fiber and total and cause-specific mortality: prospective analysis of 367,442 individuals. *BMC Med* 13:1–9. <https://doi.org/10.1186/S12916-015-0294-7/TABLES/3>
18. Ford PA, Jaceldo-Siegl K, Lee JW, Tonstad S (2016) Trans fatty acid intake is related to emotional affect in the Adventist Health Study-2. *Nutr Res* 36:509–517. <https://doi.org/10.1016/J.NUTRES.2016.01.005>
19. Kahn HA, Phillips RL, Snowdon DA, Choi W (1984) Association between reported diet and all-cause mortality. Twenty-one-year follow-up on 27, 530 adult Seventh-Day Adventists. *Am J Epidemiol* 119:775–787. <https://doi.org/10.1093/OXFORDJOURNALS.AJE.A113798>
20. Alshahrani SM, Fraser GE, Sabaté J et al (2019) Red and processed meat and mortality in a low meat intake population. *Nutrients* 11:1–13. <https://doi.org/10.3390/NU11030622>
21. Zhong VW, Van Horn L, Cornelis MC et al (2019) Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. *JAMA* 321:1081–1095. <https://doi.org/10.1001/JAMA.2019.1572>
22. Veronese N, Stubbs B, Noale M et al (2017) Fried potato consumption is associated with elevated mortality: an 8-y longitudinal cohort study. *Am J Clin Nutr* 106:162–167. <https://doi.org/10.3945/AJCN.117.154872>
23. Rabizadeh F, Mirian MS, Doosti R et al (2022) Phytochemical classification of medicinal plants used in the treatment of kidney disease based on traditional Persian medicine. *Evid Based Complement Alternat Med* 2022:1–13. <https://doi.org/10.1155/2022/8022599>
24. A Comprehensive Review on the Biological Agricultural and Pharmaceutical Properties of Secondary Metabolites Based-Plant Origin International Journal of Molecular Sciences 2023;24(4):3266. <https://doi.org/10.3390/ijms24043266>
25. Sun J, Luo S, Deng J, Yang H (2023) Phytochemicals in chronic disease prevention. *Nutrients* 15:4933. <https://doi.org/10.3390/nu15234933>
26. Zhang Y-J, Gan R-Y, Li S et al (2015) Antioxidant phytochemicals for the prevention and treatment of chronic diseases. *Molecules* 20:21138–21156. <https://doi.org/10.3390/molecules201219753>
27. Rajaram S (2003) The effect of vegetarian diet, plant foods, and phytochemicals on hemostasis and thrombosis. *Am J Clin Nutr* 78:552S–558S. <https://doi.org/10.1093/ajcn/78.3.552S>
28. Khan MAB, Hashim MJ, King JK et al (2019) Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. *J Epidemiol Glob Health* 10:107. <https://doi.org/10.2991/jegh.k.191028.001>
29. Abdelmageed ME, Shehatou GSG, Suddek GM, Salem HA (2021) Protocatechuic acid improves hepatic insulin resistance and restores vascular oxidative status in type-2 diabetic rats. *Environ Toxicol Pharmacol* 83. <https://doi.org/10.1016/j.etap.2020.103577>
30. Wang J, Huang M, Yang J, et al (2017) Anti-diabetic activity of stigmasterol from soybean oil by targeting the GLUT4 glucose transporter. *Food Nutr Res* 61. <https://doi.org/10.1080/16546628.2017.1364117>
31. Domínguez-López I, Lozano-Castellón J, Vallverdú-Queralt A et al (2023) Urinary metabolomics of phenolic compounds reveals biomarkers of type-2 diabetes within the PREDIMED trial. *Biomed Pharmacother* 162:114703. <https://doi.org/10.1016/j.biopha.2023.114703>
32. Liu D, Zhen W, Yang Z et al (2006) Genistein acutely stimulates insulin secretion in pancreatic beta-cells through a cAMP-dependent protein kinase pathway. *Diabetes* 55:1043–1050. <https://doi.org/10.2337/DIABETES.55.04.06.DB05-1089>
33. Ranilla LG, Huamán-Alvino C, Flores-Báez O et al (2019) Evaluation of phenolic antioxidant-linked in vitro bioactivity of Peruvian corn (*Zea mays* L.) diversity targeting for potential management of hyperglycemia and obesity. *J Food Sci Technol* 56:2909–2924. <https://doi.org/10.1007/s13197-019-03748-z>
34. Mahjabeen W, Khan DA, Mirza SA (2022) Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: a randomized, placebo-controlled trial. *Complement Ther Med* 66:102819. <https://doi.org/10.1016/j.ctim.2022.102819>

35. Ma N, Zhang Y (2022) Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: a randomized controlled clinical trial protocol. *Medicine* 101:e30049. <https://doi.org/10.1097/MD.00000000000030049>
36. Sarkar D, Agustinah W, Woods F et al (2017) In vitro screening and evaluation of phenolic antioxidant-linked anti-hyperglycemic functions of rabbit-eye blueberry (*Vaccinium ashei*) cultivars. *J Berry Res* 7:163–177. <https://doi.org/10.3233/JBR-170154>
37. Kim MO, Lee MH, Oi N et al (2014) [6]-Shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2. *Carcinogenesis* 35:683. <https://doi.org/10.1093/CARCIN/BGT365>
38. Talaie M (2015) Role of phytoestrogens in prevention and management of type 2 diabetes. *World J Diabetes* 6:271. <https://doi.org/10.4239/wjd.v6.i2.271>
39. Hii CST, Howell SL (1985) Effects of flavonoids on insulin secretion and 45Ca^{2+} handling in rat islets of Langerhans. *J Endocrinol* 107:1–8. <https://doi.org/10.1677/joe.0.1070001>
40. Shi GJ, Li Y, Cao QH et al (2019) In vitro and in vivo evidence that quercetin protects against diabetes and its complications: a systematic review of the literature. *Biomed Pharmacother* 109:1085–1099
41. Ansari P, Choudhury ST, Seidel V, et al (2022) Therapeutic potential of quercetin in the management of type-2 diabetes mellitus. *Life* 12
42. Chen Y-G, Li P, Li P et al (2013) α -Glucosidase inhibitory effect and simultaneous quantification of three major flavonoid glycosides in *microctis folium*. *Molecules* 18:4221–4232. <https://doi.org/10.3390/molecules18044221>
43. Balamurugan R, Duraipandiyan V, Ignacimuthu S (2011) Antidiabetic activity of γ -sitosterol isolated from *Lippia nodiflora* L. in streptozotocin induced diabetic rats. *Eur J Pharmacol* 667:410–418. <https://doi.org/10.1016/j.ejphar.2011.05.025>
44. Den Hartogh DJ, Tsiani E (2019) Antidiabetic properties of naringenin: a citrus fruit polyphenol. *Biomol Ther* 9:99. <https://doi.org/10.3390/biom9030099>
45. Ghorbani A (2017) Mechanisms of antidiabetic effects of flavonoid rutin. *Biomed Pharmacother* 96:305–312. <https://doi.org/10.1016/j.biopha.2017.10.001>
46. Pivari F, Mingione A, Brasacchio C, Soldati L (2019) Curcumin and type 2 diabetes mellitus: prevention and treatment. *Nutrients* 11:1–12. <https://doi.org/10.3390/NU11081837>
47. Chen P, Guo Z, Chen F et al (2022) Recent advances and perspectives on the health benefits of urolithin B, a bioactive natural product derived from ellagitannins. *Front Pharmacol* 13:917266. <https://doi.org/10.3389/fphar.2022.917266>
48. Li K, Zhai M, Jiang L et al (2019) Tetrahydrocurcumin ameliorates diabetic cardiomyopathy by attenuating high glucose-induced oxidative stress and fibrosis via activating the SIRT1 pathway. *Oxidative Med Cell Longev* 2019:6746907. <https://doi.org/10.1155/2019/6746907>
49. Chen X, Xie Q, Zhu Y et al (2021) Cardio-protective effect of tetrahydrocurcumin, the primary hydrogenated metabolite of curcumin in vivo and in vitro: induction of apoptosis and autophagy via PI3K/AKT/mTOR pathways. *Eur J Pharmacol* 911:174495. <https://doi.org/10.1016/j.ejphar.2021.174495>
50. Zeng Y, Xiong Y, Yang T et al (2022) Icaritin and its metabolites as potential protective phytochemicals against cardiovascular disease: from effects to molecular mechanisms. *Biomed Pharmacother* 147:112642. <https://doi.org/10.1016/J.BIOPHA.2022.112642>
51. Neto-Neves EM, da Silva Maia Bezerra Filho C, Dejana NN, de Sousa DP (2021) Ferulic acid and cardiovascular health: therapeutic and preventive potential. *Mini-Rev Med Chem* 21:1625–1637. <https://doi.org/10.2174/1389557521666210105122841>
52. Bonnefont-Rousselot D (2016) Resveratrol and cardiovascular diseases. *Nutrients* 8:1–24. <https://doi.org/10.3390/NU8050250>
53. De T, Silva P, Silva AA et al (2022) The action of phytochemicals present in cocoa in the prevention of vascular dysfunction and atherosclerosis. *J Clin Transl Res* 8:509. <https://doi.org/10.18053/jctres.08.202206.011>

54. Papakyriakopoulou P, Velidakis N, Khattab E et al (2022) Potential pharmaceutical applications of quercetin in cardiovascular diseases. *Pharmaceuticals (Basel)* 15:1–31. <https://doi.org/10.3390/PH15081019>
55. Byun MW (2012) Effect of procyanidin C1 on nitric oxide production and hyperpolarization through Ca(2+)-dependent pathway in endothelial cells. *J Med Food* 15:1032–1037. <https://doi.org/10.1089/JMF.2012.2297>
56. Osakabe N, Yasuda A, Natsume M, et al (2002) Catechins and their oligomers linked by C4 → C8 bonds are Major Cacao polyphenols and protect low-density lipoprotein from oxidation in vitro. 227:51–56. <https://doi.org/10.1177/153537020222700109>
57. Dos Santos PWS, Machado ART, De Grandis RA et al (2020) Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. *Food Chem Toxicol* 136:111047. <https://doi.org/10.1016/j.fct.2019.111047>
58. Cao C, Wu H, Vasilatos SN et al (2018) HDAC5–LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. *Int J Cancer* 143:1388–1401. <https://doi.org/10.1002/ijc.31419>
59. Gao L, Cheng D, Yang J et al (2018) Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells. *J Nutr Biochem* 56:109–115. <https://doi.org/10.1016/j.jnutbio.2018.01.015>
60. Mitsiogianni M, Trafalis DT, Franco R et al (2021) Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma. *Eur J Nutr* 60:147–158. <https://doi.org/10.1007/s00394-020-02227-y>
61. Zhang Y-M, Zhang Z-Y, Wang R-X (2020) Protective mechanisms of quercetin against myocardial ischemia reperfusion injury. *Front Physiol* 11:956. <https://doi.org/10.3389/fphys.2020.00956>
62. He C, Huang L, Lei P et al (2018) Sulforaphane normalizes intestinal flora and enhances gut barrier in mice with BBN-induced bladder cancer. *Mol Nutr Food Res* 62. <https://doi.org/10.1002/mnfr.201800427>
63. Wang C-Z, Zhang C-F, Luo Y et al (2020) Baicalein, an enteric microbial metabolite, suppresses gut inflammation and cancer progression in ApcMin/+ mice. *Clin Transl Oncol* 22:1013–1022. <https://doi.org/10.1007/s12094-019-02225-5>
64. Jiang H, Yao Q, An Y et al (2022) Baicalin suppresses the progression of Type 2 diabetes-induced liver tumor through regulating METTL3/m6A/HKDC1 axis and downstream p-JAK2/STAT1/cleaved Caspase3 pathway. *Phytomedicine* 94:153823. <https://doi.org/10.1016/j.phymed.2021.153823>
65. Yamashita S, Lin I, Oka C et al (2022) Soy isoflavone metabolite equol inhibits cancer cell proliferation in a PAP associated domain containing 5-dependent and an estrogen receptor-independent manner. *J Nutr Biochem* 100:108910. <https://doi.org/10.1016/j.jnutbio.2021.108910>
66. Zhang S, Zhao Y, Ohland C et al (2019) Microbiota facilitates the formation of the aminated metabolite of green tea polyphenol (–)-epigallocatechin-3-gallate which trap deleterious reactive endogenous metabolites. *Free Radic Biol Med* 131:332–344. <https://doi.org/10.1016/j.freeradbiomed.2018.12.023>
67. Shrimali D, Shanmugam MK, Kumar AP et al (2013) Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. *Cancer Lett* 341:139–149. <https://doi.org/10.1016/j.canlet.2013.08.023>
68. Ceci C, Lacal P, Tentori L et al (2018) Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid. *Nutrients* 10:1756. <https://doi.org/10.3390/nu10111756>
69. Chen H, Zhu B, Zhao L et al (2018) Allicin inhibits proliferation and invasion in vitro and in vivo via SHP-1-mediated STAT3 signaling in cholangiocarcinoma. *Cell Physiol Biochem* 47:641–653. <https://doi.org/10.1159/000490019>

70. Wang T, Jiang Y, Chu L et al (2017) Alpinumisoflavone suppresses tumour growth and metastasis of clear-cell renal cell carcinoma. *Am J Cancer Res* 7:999
71. Ateba SB, Mvondo MA, Djiogue S et al (2019) A pharmacological overview of alpinumisoflavone, a natural prenylated isoflavonoid. *Front Pharmacol* 10:456299. <https://doi.org/10.3389/FPHAR.2019.00952/BIBTEX>
72. Li J, Zhang C, Jiang H, Cheng J (2015) Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase/AKT pathway and suppresses breast cancer growth. *Onco Targets Ther* 8:427–435. <https://doi.org/10.2147/OTT.S76116>
73. Chen M, Wang X, Zha D et al (2016) Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. *Sci Rep* 6:1–17. <https://doi.org/10.1038/srep35468>
74. Kunnumakkara AB, Bordoloi D, Harsha C et al (2017) Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. *Clin Sci (Lond)* 131:1781–1799. <https://doi.org/10.1042/CS20160935>
75. Zhang W, Su J, Xu H et al (2017) Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells. *PLoS One* 12:1–18. <https://doi.org/10.1371/JOURNAL.PONE.0179672>
76. Sarkar FH, Li Y, Wang Z, Kong D (2010) The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. *Cancer Metastasis Rev* 29:383–394. <https://doi.org/10.1007/S10555-010-9233-4/METRICS>
77. Choi NR, Choi WG, Kwon MJ et al (2022) [6]-Gingerol induces caspase-dependent apoptosis in bladder cancer cells via MAPK and ROS signaling. *Int J Med Sci* 19:1093. <https://doi.org/10.7150/IJMS.73077>
78. Wu X, Wang W, Chen Y et al (2018) Glycyrrhizin suppresses the growth of human NSCLC Cell Line HCC827 by downregulating HMGB1 level. *Biomed Res Int* 2018:1–7. <https://doi.org/10.1155/2018/6916797>
79. Lv L, Zhang W, Li T et al (2020) Hispidulin exhibits potent anticancer activity in vitro and in vivo through activating ER stress in non-small-cell lung cancer cells. *Oncol Rep* 43:1995. <https://doi.org/10.3892/OR.2020.7568>
80. Fan X, Wang J, Wang L (2023) Licochalcone A induces cell cycle arrest in human lung squamous carcinoma cells via the PI3K/Akt signaling pathway. *Nan Fang Yi Ke Da Xue Xue Bao* 43:111–116. <https://doi.org/10.12122/J.ISSN.1673-4254.2023.01.15>
81. Subramani R, Gonzalez E, Arumugam A et al (2016) Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. *Sci Rep* 6:1–12. <https://doi.org/10.1038/SREP19819>
82. Ding W, Hu Z, Zhang Z et al (2015) Physapubescin B exhibits potent activity against human prostate cancer in vitro and in vivo. *J Agric Food Chem* 63:9504–9512. <https://doi.org/10.1021/ACS.JAFC.5B03045>
83. Wen W, Lowe G, Roberts CM et al (2018) Pterostilbene suppresses ovarian cancer growth via induction of apoptosis and blockade of cell cycle progression involving inhibition of the STAT3 pathway. *Int J Mol Sci* 19:1–12. <https://doi.org/10.3390/IJMS19071983>
84. Jang JY, Im E, Kim ND (2022) Mechanism of resveratrol-induced programmed cell death and new drug discovery against cancer: a review. *Int J Mol Sci* 23:1–28. <https://doi.org/10.3390/IJMS232213689>
85. Suppipat K, Park CS, Shen Y et al (2012) Sulforaphane induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cells. *PLoS One* 7:51251. <https://doi.org/10.1371/JOURNAL.PONE.0051251>
86. Balan DJ, Rajavel T, Das M et al (2021) Thymol induces mitochondrial pathway-mediated apoptosis via ROS generation, macromolecular damage and SOD diminution in A549 cells. *Pharmacol Rep* 73:240–254. <https://doi.org/10.1007/S43440-020-00171-6/METRICS>
87. Park JE, Kim DH, Ha E et al (2019) Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3. *Chem Biol Interact* 312:108799. <https://doi.org/10.1016/J.CBI.2019.108799>

88. Prasad S, Yadav VR, Sung B et al (2016) Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment. *Oncotarget* 7:13182–13196. <https://doi.org/10.18632/ONCOTARGET.7537>
89. Kumar S, Mathew SO, Aharwal RP et al (2023) Withaferin A: a pleiotropic anticancer agent from the indian medicinal plant withania somnifera (L.) dunal. *Pharmaceuticals* 16:1–28. <https://doi.org/10.3390/PH16020160>
90. Banc R, Rusu ME, Filip L, Popa DS (2023) The impact of ellagitannins and their metabolites through gut microbiome on the gut health and brain wellness within the gut–brain axis. *Food Secur* 12:1–41. <https://doi.org/10.3390/FOODS12020270>
91. D’andurain J, López V, Arazo-Rusindo M et al (2023) Effect of curcumin consumption on inflammation and oxidative stress in patients on hemodialysis: a literature review. *Nutrients* 15:1–18. <https://doi.org/10.3390/NU15102239>
92. Wang X, Cai H, Chen Z et al (2021) Baicalein alleviates pyroptosis and inflammation in hyperlipidemic pancreatitis by inhibiting NLRP3/Caspase-1 pathway through the miR-192-5p/TXNIP axis. *Int Immunopharmacol* 101:108315. <https://doi.org/10.1016/j.intimp.2021.108315>
93. Du G, Sun L, Zhao R et al (2016) Polyphenols: potential source of drugs for the treatment of ischaemic heart disease. *Pharmacol Ther* 162:23–34. <https://doi.org/10.1016/j.pharmthera.2016.04.008>
94. Sesso HD, Manson JE, Aragaki AK et al (2022) Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. *Am J Clin Nutr* 115:1490–1500. <https://doi.org/10.1093/ajcn/nqac055>
95. Sansone R, Rodriguez-Mateos A, Heuel J et al (2015) Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: a randomised, controlled, double-masked trial: the Flaviola Health Study. *Br J Nutr* 114:1246–1255. <https://doi.org/10.1017/S0007114515002822>
96. Reverri EJ, LaSalle CD, Franke AA, Steinberg FM (2015) Soy provides modest benefits on endothelial function without affecting inflammatory biomarkers in adults at cardiometabolic risk. *Mol Nutr Food Res* 59:323–333. <https://doi.org/10.1002/mnfr.201400270>
97. Kong M, Xie K, Lv M et al (2021) Anti-inflammatory phytochemicals for the treatment of diabetes and its complications: lessons learned and future promise. *Biomed Pharmacother* 133:110975. <https://doi.org/10.1016/j.biopha.2020.110975>
98. Alzate-Yepes T, Pérez-Palacio L, Martínez E, Osorio M (2023) Mechanisms of action of fruit and vegetable phytochemicals in colorectal cancer prevention. *Molecules* 28:4322. <https://doi.org/10.3390/molecules28114322>
99. Kotecha R, Takami A, Espinoza JL (2016) Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. *Oncotarget* 7:52517–52529. <https://doi.org/10.18632/oncotarget.9593>
100. Liao W, Zhang L, Chen X et al (2023) Targeting cancer stem cells and signalling pathways through phytochemicals: a promising approach against colorectal cancer. *Phytomedicine* 108:154524. <https://doi.org/10.1016/J.PHYMED.2022.154524>
101. Lal S, Sayeed Akhtar M, Faiyaz Khan M et al (2023) Molecular basis of phytochemical–gut microbiota interactions. *Drug Discov Today* 28:103824. <https://doi.org/10.1016/j.drudis.2023.103824>
102. Valdes AM, Walter J, Segal E, Spector TD (2018) Role of the gut microbiota in nutrition and health. *BMJ* 361:36–44. <https://doi.org/10.1136/BMJ.K2179>
103. Ganesan K, Jayachandran M, Xu B (2020) Diet-derived phytochemicals targeting colon cancer stem cells and microbiota in colorectal cancer. *Int J Mol Sci* 21:3976. <https://doi.org/10.3390/ijms21113976>
104. Santa K, Kumazawa Y, Nagaoka I (2023) Prevention of metabolic syndrome by phytochemicals and vitamin D. *Int J Mol Sci* 24:2627. <https://doi.org/10.3390/ijms24032627>

105. Barber TM, Valsamakis G, Mastorakos G et al (2021) Dietary influences on the microbiota–gut–brain axis. *Int J Mol Sci* 22:3502. <https://doi.org/10.3390/ijms22073502>
106. Thursby E, Juge N (2017) Introduction to the human gut microbiota. *Biochem J* 474:1823–1836. <https://doi.org/10.1042/BCJ20160510>
107. Jin P, Wang K, Huang C, Nice EC (2017) Mining the fecal proteome: from biomarkers to personalised medicine. *Expert Rev Proteomics* 14:445–459. <https://doi.org/10.1080/14789450.2017.1314786>
108. Bäckhed F, Roswall J, Peng Y et al (2015) Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe* 17:690–703. <https://doi.org/10.1016/j.chom.2015.04.004>
109. Zheng D, Liwinski T, Elinav E (2020) Interaction between microbiota and immunity in health and disease. *Cell Res* 30:492–506. <https://doi.org/10.1038/s41422-020-0332-7>
110. Mukhopadhyay I, Segal JP, Carding SR et al (2019) The gut virome: the ‘missing link’ between gut bacteria and host immunity? *Ther Adv Gastroenterol* 12:1–17. <https://doi.org/10.1177/1756284819836620>
111. Kwon C, Ediriweera MK, Kim Cho S (2023) Interplay between phytochemicals and the colonic microbiota. *Nutrients* 15:1989. <https://doi.org/10.3390/nu15081989>
112. Skrypnik K, Suliburska J (2018) Association between the gut microbiota and mineral metabolism. *J Sci Food Agric* 98:2449–2460. <https://doi.org/10.1002/jsfa.8724>
113. Zhang L, Liu C, Jiang Q, Yin Y (2021) Butyrate in energy metabolism: there is still more to learn. *Trends Endocrinol Metab* 32:159–169. <https://doi.org/10.1016/j.tem.2020.12.003>
114. Martin AM, Sun EW, Rogers GB, Keating DJ (2019) The influence of the gut microbiome on host metabolism through the regulation of gut hormone release. *Front Physiol* 10:1–11. <https://doi.org/10.3389/fphys.2019.00428>
115. Strandwitz P (2018) Neurotransmitter modulation by the gut microbiota. *Brain Res* 1693:128–133. <https://doi.org/10.1016/j.brainres.2018.03.015>
116. Larrosa Pérez M, Martínez-López S, González-Rodríguez LG et al (2022) Microbiota-diet interactions: towards personalized nutrition. *Nutr Hosp* 39:39–43. <https://doi.org/10.20960/nh.04309>
117. Rooks MG, Garrett WS (2016) Gut microbiota, metabolites and host immunity. *Nat Rev Immunol* 16:341–352. <https://doi.org/10.1038/nri.2016.42>
118. Koppel N, Maini Rekdal V, Balskus EP (2017) Chemical transformation of xenobiotics by the human gut microbiota. *Science* 356:2770–2775. <https://doi.org/10.1126/science.aag2770>
119. Jandhyala SM (2015) Role of the normal gut microbiota. *World J Gastroenterol* 21:8787. <https://doi.org/10.3748/wjg.v21.i29.8787>
120. Ghosh TS, Rampelli S, Jeffery IB et al (2020) Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. *Gut* 69:1218–1228. <https://doi.org/10.1136/gutjnl-2019-319654>
121. Rothschild D, Weissbrod O, Barkan E et al (2018) Environment dominates over host genetics in shaping human gut microbiota. *Nature* 555:210–215. <https://doi.org/10.1038/nature25973>
122. von Schwartzberg RJ, Bisanz JE, Lyalina S et al (2021) Caloric restriction disrupts the microbiota and colonization resistance. *Nature* 595:272–277. <https://doi.org/10.1038/s41586-021-03663-4>
123. Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF (2017) The microbiota–gut–brain axis in obesity. *Lancet Gastroenterol Hepatol* 2:747–756. [https://doi.org/10.1016/S2468-1253\(17\)30147-4](https://doi.org/10.1016/S2468-1253(17)30147-4)
124. Hagan T, Cortese M, Roupheal N et al (2019) Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. *Cell* 178:1313–1328.e13. <https://doi.org/10.1016/j.cell.2019.08.010>
125. Chen X, Pan S, Li F et al (2022) Plant-derived bioactive compounds and potential health benefits: involvement of the gut microbiota and its metabolic activity. *Biomol Ther* 12:1871. <https://doi.org/10.3390/biom12121871>

126. Pandey KB, Rizvi SI (2009) Plant polyphenols as dietary antioxidants in human health and disease. *Oxidative Med Cell Longev* 2:270–278. <https://doi.org/10.4161/oxim.2.5.9498>
127. Mithul Aravind S, Wichienchot S, Tsao R et al (2021) Role of dietary polyphenols on gut microbiota, their metabolites and health benefits. *Food Res Int* 142:110189. <https://doi.org/10.1016/j.foodres.2021.110189>
128. Rodríguez-Daza MC, Pulido-Mateos EC, Lupien-Meilleur J et al (2021) Polyphenol-mediated gut microbiota modulation: toward prebiotics and further. *Front Nutr* 8:1–24. <https://doi.org/10.3389/fnut.2021.689456>
129. Gagnon E, Mitchell PL, Manikpurage HD et al (2023) Impact of the gut microbiota and associated metabolites on cardiometabolic traits, chronic diseases and human longevity: a Mendelian randomization study. *J Transl Med* 21:60. <https://doi.org/10.1186/s12967-022-03799-5>
130. Yin R, Kuo H-C, Hudlikar R et al (2019) Gut microbiota, dietary phytochemicals, and benefits to human health. *Curr Pharmacol Rep* 5:332–344. <https://doi.org/10.1007/s40495-019-00196-3>
131. Al-Harbi SA, Abdulrahman AO, Zamzami MA, Khan MI (2021) Urolithins: the gut based polyphenol metabolites of ellagitannins in cancer prevention, a review. *Front Nutr* 8:1–15. <https://doi.org/10.3389/fnut.2021.647582>
132. Lin I-C, Wu J-Y, Fang C-Y et al (2023) Absorption and metabolism of urolithin A and ellagic acid in mice and their cytotoxicity in human colorectal cancer cells. *Evid Based Complement Alternat Med* 2023:1–11. <https://doi.org/10.1155/2023/8264716>
133. Beltrán D, Romo-Vaquero M, Espín JC et al (2018) Ellagibacter isourolithinifaciens gen. nov., sp. nov., a new member of the family Eggerthellaceae, isolated from human gut. *Int J Syst Evol Microbiol* 68:1707–1712. <https://doi.org/10.1099/ijsem.0.002735>
134. Selma MV, Beltrán D, García-Villalba R et al (2014) Description of urolithin production capacity from ellagic acid of two human intestinal *Gordonibacter* species. *Food Funct* 5:1779–1784. <https://doi.org/10.1039/C4FO00092G>
135. Li K, Xiao Y, Bian J et al (2022) Ameliorative effects of gut microbial metabolite urolithin A on pancreatic diseases. *Nutrients* 14:2549. <https://doi.org/10.3390/nu14122549>
136. West CE, Renz H, Jenmalm MC et al (2015) The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies. *J Allergy Clin Immunol* 135:3–13. <https://doi.org/10.1016/j.jaci.2014.11.012>
137. Vaduganathan M, Mensah GA, Turco JV et al (2022) The global burden of cardiovascular diseases and risk: a compass for future health. *J Am Coll Cardiol* 80:2361–2371
138. Viguiouk E, Kendall CW, Kahleová H et al (2019) Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. *Clin Nutr* 38:1133–1145. <https://doi.org/10.1016/j.clnu.2018.05.032>
139. Wang T, Kroeger CM, Cassidy S et al (2023) Vegetarian dietary patterns and cardiometabolic risk in people with or at high risk of cardiovascular disease: a systematic review and meta-analysis. *JAMA Netw Open* 6:e2325658–e2325658. <https://doi.org/10.1001/JAMANETWORKOPEN.2023.25658>
140. Fraser GE, Ch MBB (1999) Nut consumption, lipids, and risk of a coronary event. *Clin Cardiol* 22:11–15. <https://doi.org/10.1002/CLC.4960221504>
141. Toohy ML, Harris MA, Melby CL et al (1998) Cardiovascular disease risk factors are lower in African-American vegans compared to Lacto-Ovo-vegetarians. *J Am Coll Nutr* 17:425–434. <https://doi.org/10.1080/07315724.1998.10718789>
142. Guerrero-Flores GN, Pacheco FJ, Boskovic DS et al (2023) Sialic acids Neu 5Ac and KDN in adipose tissue samples from individuals following habitual vegetarian or non-vegetarian dietary patterns. *Sci Rep* 13:12593. <https://doi.org/10.1038/s41598-023-38102-z>
143. Dybvik JS, Svendsen M, Aune D (2023) Vegetarian and vegan diets and the risk of cardiovascular disease, ischemic heart disease and stroke: a systematic review and meta-analysis of prospective cohort studies. *Eur J Nutr* 62:51–69. <https://doi.org/10.1007/S00394-022-02942-8/FIGURES/3>

144. Satija A, Hu FB (2018) Plant-based diets and cardiovascular health. *Trends Cardiovasc Med* 28:437–441. <https://doi.org/10.1016/J.TCM.2018.02.004>
145. Ornish D, Scherwitz LW, Billings JH et al (1998) Intensive lifestyle changes for reversal of coronary heart disease. *JAMA* 280:2001–2007. <https://doi.org/10.1001/JAMA.280.23.2001>
146. Kumar N, Goel N (2019) Phenolic acids: natural versatile molecules with promising therapeutic applications. *Biotechnol Reports* 24:e00370. <https://doi.org/10.1016/J.BTRE.2019.E00370>
147. Randhawa MA, Khan AA, Javed MS, Sajid MW (2015) Green leafy vegetables: a health promoting source. *Handbook of Fertility: Nutrition, Diet, Lifestyle and Reproductive Health* 205–220. <https://doi.org/10.1016/B978-0-12-800872-0.00018-4>
148. Kumar A, Nirmal P, Kumar M et al (2023) Major phytochemicals: recent advances in health benefits and extraction method. *Molecules* 28:887. <https://doi.org/10.3390/MOLECULES28020887>
149. Ikeda I, Tanaka K, Sugano M et al (1988) Inhibition of cholesterol absorption in rats by plant sterols. *J Lipid Res* 29:1573–1582. [https://doi.org/10.1016/S0022-2275\(20\)38403-0](https://doi.org/10.1016/S0022-2275(20)38403-0)
150. Nissinen M, Gylling H, Vuoristo M, Miettinen TA (2002) Micellar distribution of cholesterol and phytosterols after duodenal plant stanol ester infusion. *Am J Physiol Gastrointest Liver Physiol* 282:G1009-15. <https://doi.org/10.1152/AJPGI.00446.2001/ASSET/IMAGES/LARGE/H30620835001.JPEG>
151. Bai Y, Wang X, Zhao S et al (2015) Sulforaphane protects against cardiovascular disease via Nrf2 activation. *Oxidative Med Cell Longev* 2015:1–13. <https://doi.org/10.1155/2015/407580>
152. Arauna D, Furriana M, Espinosa-Parrilla Y et al (2019) Natural bioactive compounds as protectors of mitochondrial dysfunction in cardiovascular diseases and aging. *Molecules* 24:4259. <https://doi.org/10.3390/MOLECULES24234259>
153. Liu H, Zhang Y, Sun S, Wang S (2019) Efficacy of terpenoid in attenuating aortic atherosclerosis in apolipoprotein-E deficient mice: a meta-analysis of animal studies. *Biomed Res Int* 2019:1–12. <https://doi.org/10.1155/2019/2931831>
154. Kazemian N, Mahmoudi M, Halperin F et al (2020) Gut microbiota and cardiovascular disease: opportunities and challenges. *Microbiome* 8:36. <https://doi.org/10.1186/s40168-020-00821-0>
155. Istas G, Wood E, Le Sayec M et al (2019) Effects of aronia berry (poly)phenols on vascular function and gut microbiota: a double-blind randomized controlled trial in adult men. *Am J Clin Nutr* 110:316–329. <https://doi.org/10.1093/ajcn/nqz075>
156. Haghikia A, Zimmermann F, Schumann P et al (2022) Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. *Eur Heart J* 43:518–533. <https://doi.org/10.1093/eurheartj/ehab644>
157. Chen M, Yi L, Zhang Y et al (2016) Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. *MBio* 7:1–14. <https://doi.org/10.1128/mBio.02210-15>
158. Morand C, Dubray C, Milenkovic D et al (2011) Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. *Am J Clin Nutr* 93:73–80. <https://doi.org/10.3945/ajcn.110.004945>
159. Xu M, Lv C, Wang H et al (2022) Peanut skin extract ameliorates high-fat diet-induced atherosclerosis by regulating lipid metabolism, inflammation reaction and gut microbiota in ApoE^{-/-} mice. *Food Res Int* 154:111014. <https://doi.org/10.1016/j.foodres.2022.111014>
160. Li S, You J, Wang Z et al (2021) Curcumin alleviates high-fat diet-induced hepatic steatosis and obesity in association with modulation of gut microbiota in mice. *Food Res Int* 143:110270. <https://doi.org/10.1016/j.foodres.2021.110270>
161. Rodríguez-Daza M-C, Daoust L, Boutkrabt L et al (2020) Wild blueberry proanthocyanidins shape distinct gut microbiota profile and influence glucose homeostasis and intestinal phenotypes in high-fat high-sucrose fed mice. *Sci Rep* 10:2217. <https://doi.org/10.1038/s41598-020-58863-1>

162. Zurbau A, Noronha JC, Khan TA et al (2021) The effect of oat β -glucan on postprandial blood glucose and insulin responses: a systematic review and meta-analysis. *Eur J Clin Nutr* 75:1540–1554. <https://doi.org/10.1038/s41430-021-00875-9>
163. Ahmad FB, Cisewski JA, Xu J, Anderson RN (2023) Provisional mortality data — United States, 2022. *MMWR Morb Mortal Wkly Rep* 72:488–492. <https://doi.org/10.15585/MMWR.MM7218A3>
164. Allemani C, Weir HK, Carreira H et al (2023) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Our World Data* 385:977–1010. [https://doi.org/10.1016/S0140-6736\(14\)62038-9](https://doi.org/10.1016/S0140-6736(14)62038-9)
165. Pacheco SOS, Pacheco FJ, Zapata GMJ et al (2016) Food habits, lifestyle factors, and risk of prostate cancer in central Argentina: a case control study involving self-motivated health behavior modifications after diagnosis. *Nutrients* 8:1–22. <https://doi.org/10.3390/nu8070419>
166. Watling CZ, Schmidt JA, Dunneram Y et al (2022) Risk of cancer in regular and low meat-eaters, fish-eaters, and vegetarians: a prospective analysis of UK Biobank participants. *BMC Med* 20:1–13. <https://doi.org/10.1186/S12916-022-02256-W/TABLES/2>
167. Stein CJ, Colditz GA (2004) Modifiable risk factors for cancer. *Br J Cancer* 90:299. <https://doi.org/10.1038/SJ.BJC.6601509>
168. Nelson DE, Jarman DW, Rehm J et al (2013) Alcohol-attributable cancer deaths and years of potential life lost in the United States. *Am J Public Health* 103:641. <https://doi.org/10.2105/AJPH.2012.301199>
169. Key TJ, Allen NE, Spencer EA, Travis RC (2002) The effect of diet on risk of cancer. *Lancet* 360:861–868. [https://doi.org/10.1016/S0140-6736\(02\)09958-0](https://doi.org/10.1016/S0140-6736(02)09958-0)
170. Key TJ, Appleby PN, Spencer EA et al (2009) Cancer incidence in vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford). *Am J Clin Nutr* 89. <https://doi.org/10.3945/AJCN.2009.26736M>
171. Singh PN, Fraser GE (1998) Dietary risk factors for colon cancer in a low-risk population. *Am J Epidemiol* 148:761–774. <https://doi.org/10.1093/OXFORDJOURNALS.AJE.A009697>
172. DeClercq V, Nearing JT, Sweeney E (2022) Plant-based diets and cancer risk: what is the evidence? *Curr Nutr Rep* 11:354–369. <https://doi.org/10.1007/S13668-022-00409-0>
173. Huang Y, Cao D, Chen Z et al (2021) Red and processed meat consumption and cancer outcomes: umbrella review. *Food Chem* 356:129697. <https://doi.org/10.1016/J.FOODCHEM.2021.129697>
174. George BP, Chandran R, Abrahamse H (2021) Role of phytochemicals in cancer chemoprevention: insights. *Antioxidants* 10:1–23. <https://doi.org/10.3390/ANTIOX10091455>
175. Rahman MA, Hannan MA, Dash R et al (2021) Phytochemicals as a complement to cancer chemotherapy: pharmacological modulation of the autophagy-apoptosis pathway. *Front Pharmacol* 12:1–20. <https://doi.org/10.3389/FPHAR.2021.639628/BIBTEX>
176. Craig WJ, Mangels AR, Fresán U et al (2021) The safe and effective use of plant-based diets with guidelines for health professionals. *Nutrients* 4144:2–29. <https://doi.org/10.3390/nu13114144>
177. Choudhari AS, Mandave PC, Deshpande M et al (2019) Phytochemicals in cancer treatment: from preclinical studies to clinical practice. *Front Pharmacol* 10:1–17. <https://doi.org/10.3389/FPHAR.2019.01614>
178. Le Y, Wang B, Xue M (2022) Nutraceuticals use and type 2 diabetes mellitus. *Curr Opin Pharmacol* 62:168–176. <https://doi.org/10.1016/J.COPH.2021.12.004>
179. Kang I, Buckner T, Shay NF et al (2016) Improvements in metabolic health with consumption of ellagic acid and subsequent conversion into urolithins: evidence and mechanisms. *Adv Nutr* 7:961. <https://doi.org/10.3945/AN.116.012575>
180. Rauf A, Imran M, Butt MS et al (2018) Resveratrol as an anti-cancer agent: a review. *Crit Rev Food Sci Nutr* 58:1428–1447. <https://doi.org/10.1080/10408398.2016.1263597>
181. Bai X, Cheng Y, Wan H et al (2022) Natural compound allicin containing Thiosulfinate Moieties as Transmembrane Protein 16A (TMEM16A) ion channel inhibitor for food adjuvant

- therapy of lung cancer. *J Agric Food Chem*. https://doi.org/10.1021/ACS.JAFC.2C06723/SUPPL_FILE/JF2C06723_SI_001.PDF
182. Wu R, Wang L, Yin R et al (2020) Epigenetics/epigenomics and prevention by curcumin of early stages of inflammatory-driven colon cancer. *Mol Carcinog* 59:227–236. <https://doi.org/10.1002/mc.23146>
183. Cruz–Correa M, Shoskes DA, Sanchez P, et al (2006) Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. *Clin Gastroenterol Hepatol* 4:1035–1038. doi:<https://doi.org/10.1016/j.cgh.2006.03.020>
184. Sharma M, Arora I, Stoll ML et al (2020) Nutritional combinatorial impact on the gut microbiota and plasma short-chain fatty acids levels in the prevention of mammary cancer in Her 2/neu estrogen receptor-negative transgenic mice. *PLoS One* 15:e0234893. <https://doi.org/10.1371/journal.pone.0234893>
185. Messaoudene M, Pidgeon R, Richard C et al (2022) A natural polyphenol exerts antitumor activity and circumvents anti–PD-1 resistance through effects on the gut microbiota. *Cancer Discov* 12:1070–1087. <https://doi.org/10.1158/2159-8290.CD-21-0808>
186. Hilakivi-Clarke L, Verma V, McDermott M et al (2022) Foods may modify responsiveness to cancer immune checkpoint blockers by altering both the gut microbiota and activation of estrogen receptors in immune cells. *Front Microbiomes* 1:1–32. <https://doi.org/10.3389/frmbi.2022.1049688>
187. Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes Atlas, 9th ed. *Diabetes Res Clin Pract* 157:107843. <https://doi.org/10.1016/j.diabres.2019.107843>
188. Sun H, Saeedi P, Karuranga S et al (2023) Erratum to “IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045”. *Diabetes Res Clin Pract* 204:110945
189. Reach G, Pechtner V, Gentilella R et al (2017) Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. *Diabetes Metab* 43:501–511
190. Alam S, Sarker MMR, Sultana TN et al (2022) Antidiabetic phytochemicals from medicinal plants: prospective candidates for new drug discovery and development. *Front Endocrinol (Lausanne)* 13:800714
191. McGovern A, Tippu Z, Hinton W et al (2018) Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab* 20:1040–1043. <https://doi.org/10.1111/dom.13160>
192. Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 43:487–493. <https://doi.org/10.2337/dci19-0066>
193. Artasensi A, Pedretti A, Vistoli G, Fumagalli L (2020) Type 2 diabetes mellitus: a review of multi-target drugs. *Molecules* 25:1987
194. Onaolapo AY, Onaolapo OJ (2020) Nutraceuticals and diet-based phytochemicals in type 2 diabetes mellitus: from whole food to components with defined roles and mechanisms. *Curr Diabetes Rev* 16:12–25. <https://doi.org/10.2174/1573399814666181031103930>
195. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM et al (2015) Discovery and resupply of pharmacologically active plant-derived natural products: a review. *Biotechnol Adv* 33:1582–1614
196. Chang CLT, Lin Y, Bartolome AP et al (2013) Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. *Evid Based Complement Alternat Med* 2013:378657
197. Coman C, Rugina OD, Socaciu C (2012) Plants and natural compounds with antidiabetic action. *Not Bot Horti Agrobot Cluj Napoca* 40:314–325
198. Rosenzweig T, Sampson SR (2021) Activation of insulin signaling by botanical products. *Int J Mol Sci* 22

199. Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with diabetes or prediabetes: a consensus report. *Diabetes Care* 42:731–754
200. Petroni ML, Brodosi L, Marchignoli F et al (2021) Nutrition in patients with type 2 diabetes: current knowledge and remaining challenges. *Nutrients* 13:2748
201. Martín-Peláez S, Fito M, Castaner O (2020) Mediterranean diet effects on type 2 diabetes prevention, disease progression, and related mechanisms. A review. *Nutrients* 12:1–15
202. Sarkar D, Christopher A, Shetty K (2022) Phenolic bioactives from plant-based foods for glycemic control. *Front Endocrinol (Lausanne)* 12:727503
203. Onaolapo AY, Onaolapo OJ, Adewole SA (2011) Ethanolic extract of *ocimum grattissimum* leaves (linn.) rapidly lowers blood glucose levels in diabetic wistar rats. *Macedonian J Med Sci* 4:351–357. <https://doi.org/10.3889/MJMS.1857-5773.2011.0172>
204. Onaolapo AY, Onaolapo OJ (2012) *Ocimum Grattissimum* Linn causes dose dependent Hepatotoxicity in streptozotocin-induced diabetic Wistar rats. *Macedonian J Med Sci* 5:17–25. <https://doi.org/10.3889/MJMS.1857-5773.2011.0206>
205. Mollica A, Zengin G, Locatelli M et al (2017) Anti-diabetic and anti-hyperlipidemic properties of *Capparis spinosa* L.: in vivo and in vitro evaluation of its nutraceutical potential. *J Funct Foods* 35:32–42. <https://doi.org/10.1016/J.JFF.2017.05.001>
206. Mollica A, Zengin G, Locatelli M et al (2017) An assessment of the nutraceutical potential of *Juglans regia* L. leaf powder in diabetic rats. *Food Chem Toxicol* 107:554–564. <https://doi.org/10.1016/J.FCT.2017.03.056>
207. Patel D, Prasad S, Kumar R, Hemalatha S (2012) An overview on antidiabetic medicinal plants having insulin mimetic property. *Asian Pac J Trop Biomed* 2:320–330. [https://doi.org/10.1016/S2221-1691\(12\)60032-X](https://doi.org/10.1016/S2221-1691(12)60032-X)
208. Ramírez-Alarcón K, Victoriano M, Mardones L et al (2021) Phytochemicals as potential epidrugs in type 2 diabetes mellitus. *Front Endocrinol (Lausanne)* 12:656978
209. Rashad H, Metwally FM, Ezzat SM et al (2017) Randomized double-blinded pilot clinical study of the antidiabetic activity of balanites aegyptiaca and uplc-esi-ms/ms identification of its metabolites. *Pharm Biol* 55:1954–1961. <https://doi.org/10.1080/13880209.2017.1354388>
210. Leyva-Soto A, Chavez-Santoscoy RA, Lara-Jacobo LR et al (2018) Daily consumption of chocolate rich in flavonoids decreases cellular genotoxicity and improves biochemical parameters of lipid and glucose metabolism. *Molecules* 23:1–12. <https://doi.org/10.3390/molecules23092220>
211. Delpino FM, Figueiredo LM (2022) Resveratrol supplementation and type 2 diabetes: a systematic review and meta-analysis. *Crit Rev Food Sci Nutr* 62:4465–4480
212. Huang DD, Shi G, Jiang Y et al (2020) A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. *Biomed Pharmacother* 125:109767
213. Ansari P, Choudhury ST, Seidel V et al (2022) Therapeutic potential of quercetin in the management of type-2 diabetes mellitus. *Life* 12:1146
214. Bellavite P, Fazio S, Affuso F (2023) A descriptive review of the action mechanisms of berberine, quercetin and silymarin on insulin resistance/hyperinsulinemia and cardiovascular prevention. *Molecules* 28
215. Cunningham AL, Stephens JW, Harris DA (2021) Gut microbiota influence in type 2 diabetes mellitus (T2DM). *Gut Pathogens* 13(1):1–13. <https://doi.org/10.1186/S13099-021-00446-0>
216. Gurung M, Li Z, You H et al (2020) Role of gut microbiota in type 2 diabetes pathophysiology. *EBioMedicine* 51:1–9. <https://doi.org/10.1016/J.EBIOM.2019.11.051/ATTACHMENT/7BDEFFA7-1D21-4F65-B0F8-FC20EE7A0065/MMC1.XLSX>
217. Zhang L, Chu J, Hao W, et al (2021) Gut microbiota and type 2 diabetes mellitus: association, mechanism, and translational applications. *Mediat Inflamm* 2021. <https://doi.org/10.1155/2021/5110276>
218. Brahe LK, Astrup A, Larsen LH (2013) Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? *Obes Rev* 14:950–959. <https://doi.org/10.1111/OBR.12068>

219. Sanna S, van Zuydam NR, Mahajan A et al (2019) Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. *Nat Genet* 51(4):600–605. <https://doi.org/10.1038/s41588-019-0350-x>
220. van den Munckhof ICL, Kurilshikov A, ter Horst R et al (2018) Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. *Obes Rev* 19:1719–1734. <https://doi.org/10.1111/OBR.12750>
221. Iatcu CO, Steen A, Covasa M (2022) Gut microbiota and complications of type-2 diabetes. *Nutrients* 14:1–13. <https://doi.org/10.3390/NU14010166>
222. Suganya K, Koo BS (2020) Gut–brain axis: role of gut microbiota on neurological disorders and how probiotics/prebiotics beneficially modulate microbial and immune pathways to improve brain functions. *Int J Mol Sci* 21:1–29. <https://doi.org/10.3390/IJMS21207551>
223. Garcia-Gutierrez E, Narbad A, Rodríguez JM (2020) Autism spectrum disorder associated with gut microbiota at immune, metabolomic, and neuroactive level. *Front Neurosci* 14:1–14. <https://doi.org/10.3389/fnins.2020.578666>
224. Samochowicz J, Misiak B (2021) Gut microbiota and microbiome in schizophrenia. *Curr Opin Psychiatry* 34:503–507. <https://doi.org/10.1097/YCO.0000000000000733>
225. Tengeler AC, Dam SA, Wiesmann M et al (2020) Gut microbiota from persons with attention-deficit/hyperactivity disorder affects the brain in mice. *Microbiome* 8:44. <https://doi.org/10.1186/s40168-020-00816-x>
226. Xu M, Huang H, Mo X, et al (2021) Quercetin-3-O-glucuronide alleviates cognitive deficit and toxicity in A β 1-42-induced AD-like mice and SH-SY5Y cells. *Mol Nutr Food Res* 65. <https://doi.org/10.1002/mnfr.202000660>
227. Zhang F, Zhou Y, Chen H et al (2022) Curcumin alleviates DSS-induced anxiety-like behaviors via the microbial-brain-gut axis. *Oxidative Med Cell Longev* 2022:1–19. <https://doi.org/10.1155/2022/6244757>
228. Beydoun MA, Beydoun HA, Boueiz A et al (2013) Antioxidant status and its association with elevated depressive symptoms among US adults: National Health and Nutrition Examination Surveys 2005–6. *Br J Nutr* 109:1714–1729. <https://doi.org/10.1017/S0007114512003467>